CONTEXT: MDMA (3,4-methylenedioxymethamphetamine, also popularly known as "ecstasy") is a popular recreational drug that produces loss of serotonin axons in animal models. Whether MDMA produces chronic reductions in serotonin signaling in humans remains controversial. OBJECTIVE: To determine whether MDMA use is associated with chronic reductions in serotonin signaling in the cerebral cortex of women as reflected by increased serotonin(2A) receptor levels. DESIGN: Cross-sectional case-control study comparing serotonin(2A) receptor levels in abstinent female MDMA polydrug users with those in women who did not use MDMA (within-group design assessing the association of lifetime MDMA use and serotonin(2A) receptors). Case participants were abstinent from MDMA use for at least 90 days as verified by analysis of hair samples. The serotonin(2A) receptor levels in the cerebral cortex were determined using serotonin(2A)-specific positron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer. SETTING: Academic medical center research laboratory. PARTICIPANTS: A total of 14 female MDMA users and 10 women who did not use MDMA (controls). The main exclusion criteria were nondrug-related DSM-IV Axis I psychiatric disorders and general medical illness. MAIN OUTCOME MEASURES: Cortical serotonin(2A) receptor nondisplaceable binding potential (serotonin(2A)BP(ND)). RESULTS: MDMA users had increased serotonin(2A)BP(ND) in occipital-parietal (19.7%), temporal (20.5%), occipitotemporal-parietal (18.3%), frontal (16.6%), and frontoparietal (18.5%) regions (corrected P < .05). Lifetime MDMA use was positively associated with serotonin(2A)BP(ND) in frontoparietal (β = 0.665; P = .007), occipitotemporal (β = 0.798; P = .002), frontolimbic (β = 0.634; P = .02), and frontal (β = 0.691; P = .008) regions. In contrast, there were no regions in which MDMA use was inversely associated with receptor levels. There were no statistically significant effects of the duration of MDMA abstinence on serotonin(2A)BP(ND). CONCLUSIONS: The recreational use of MDMA is associated with long-lasting increases in serotonin(2A) receptor density. Serotonin(2A) receptor levels correlate positively with lifetime MDMA use and do not decrease with abstinence. These results suggest that MDMA use produces chronic serotonin neurotoxicity in humans. Given the broad role of serotonin in human brain function, the possibility for therapeutic MDMA use, and the widespread recreational popularity of this drug, these results have critical public health implications.
CONTEXT: MDMA (3,4-methylenedioxymethamphetamine, also popularly known as "ecstasy") is a popular recreational drug that produces loss of serotonin axons in animal models. Whether MDMA produces chronic reductions in serotonin signaling in humans remains controversial. OBJECTIVE: To determine whether MDMA use is associated with chronic reductions in serotonin signaling in the cerebral cortex of women as reflected by increased serotonin(2A) receptor levels. DESIGN: Cross-sectional case-control study comparing serotonin(2A) receptor levels in abstinent female MDMA polydrug users with those in women who did not use MDMA (within-group design assessing the association of lifetime MDMA use and serotonin(2A) receptors). Case participants were abstinent from MDMA use for at least 90 days as verified by analysis of hair samples. The serotonin(2A) receptor levels in the cerebral cortex were determined using serotonin(2A)-specific positron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer. SETTING: Academic medical center research laboratory. PARTICIPANTS: A total of 14 female MDMA users and 10 women who did not use MDMA (controls). The main exclusion criteria were nondrug-related DSM-IV Axis I psychiatric disorders and general medical illness. MAIN OUTCOME MEASURES: Cortical serotonin(2A) receptor nondisplaceable binding potential (serotonin(2A)BP(ND)). RESULTS:MDMA users had increased serotonin(2A)BP(ND) in occipital-parietal (19.7%), temporal (20.5%), occipitotemporal-parietal (18.3%), frontal (16.6%), and frontoparietal (18.5%) regions (corrected P < .05). Lifetime MDMA use was positively associated with serotonin(2A)BP(ND) in frontoparietal (β = 0.665; P = .007), occipitotemporal (β = 0.798; P = .002), frontolimbic (β = 0.634; P = .02), and frontal (β = 0.691; P = .008) regions. In contrast, there were no regions in which MDMA use was inversely associated with receptor levels. There were no statistically significant effects of the duration of MDMA abstinence on serotonin(2A)BP(ND). CONCLUSIONS: The recreational use of MDMA is associated with long-lasting increases in serotonin(2A) receptor density. Serotonin(2A) receptor levels correlate positively with lifetime MDMA use and do not decrease with abstinence. These results suggest that MDMA use produces chronic serotonin neurotoxicity in humans. Given the broad role of serotonin in human brain function, the possibility for therapeutic MDMA use, and the widespread recreational popularity of this drug, these results have critical public health implications.
Authors: John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan Journal: Neuroimage Date: 2009-03-02 Impact factor: 6.556
Authors: Neil D Woodward; David H Zald; Zhaohua Ding; Patrizia Riccardi; M Sib Ansari; Ronald M Baldwin; Ronald L Cowan; Rui Li; Robert M Kessler Journal: Neuroimage Date: 2009-02-05 Impact factor: 6.556
Authors: João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho Journal: Mol Neurobiol Date: 2009-04-17 Impact factor: 5.590
Authors: David H Zald; Ronald L Cowan; Patrizia Riccardi; Ronald M Baldwin; M Sib Ansari; Rui Li; Evan S Shelby; Clarence E Smith; Maureen McHugo; Robert M Kessler Journal: J Neurosci Date: 2008-12-31 Impact factor: 6.167
Authors: V Raj; H C Liang; N D Woodward; A L Bauernfeind; J Lee; M S Dietrich; S Park; R L Cowan Journal: J Psychopharmacol Date: 2009-03-20 Impact factor: 4.153
Authors: Joshua W Buckholtz; Michael T Treadway; Ronald L Cowan; Neil D Woodward; Stephen D Benning; Rui Li; M Sib Ansari; Ronald M Baldwin; Ashley N Schwartzman; Evan S Shelby; Clarence E Smith; David Cole; Robert M Kessler; David H Zald Journal: Nat Neurosci Date: 2010-03-14 Impact factor: 24.884
Authors: Michael D Berquist; Sebastian Leth-Petersen; Jesper Langgaard Kristensen; William E Fantegrossi Journal: Psychopharmacology (Berl) Date: 2019-11-15 Impact factor: 4.530
Authors: Tristan J Watkins; Vidya Raj; Junghee Lee; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Ronald M Salomon; Sohee Park; Margaret M Benningfield; Christina R Di Iorio; Ronald L Cowan Journal: Psychopharmacology (Berl) Date: 2012-12-16 Impact factor: 4.530
Authors: Elisabet Cuyas; Patricia Robledo; Nieves Pizarro; Magí Farré; Elena Puerta; Norberto Aguirre; Rafael de la Torre Journal: Neurotox Res Date: 2013-08-15 Impact factor: 3.911
Authors: Oliver G Bosch; Michael Wagner; Frank Jessen; Kai-Uwe Kühn; Alexius Joe; Erich Seifritz; Wolfgang Maier; Hans-Jürgen Biersack; Boris B Quednow Journal: PLoS One Date: 2013-04-09 Impact factor: 3.240